Editorial
doi: 10.1200/JCO.20.02688.
Epub 2020 Sep 20.
CDK4/6 Inhibition in Early-Stage Breast Cancer: The New Standard?
Affiliations
- PMID: 32954928
- DOI: 10.1200/JCO.20.02688
Item in Clipboard
Editorial
CDK4/6 Inhibition in Early-Stage Breast Cancer: The New Standard?
J Clin Oncol.
.
No abstract available
Comment on
-
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).J Clin Oncol. 2020 Dec 1;38(34):3987-3998. doi: 10.1200/JCO.20.02514. Epub 2020 Sep 20. J Clin Oncol. 2020. PMID: 32954927 Free PMC article. Clinical Trial.
Similar articles
-
CDK4/6 inhibitors for HR+HER2- early stage breast cancer - when to escalate treatment?Nat Rev Clin Oncol. 2021 Feb;18(2):67-68. doi: 10.1038/s41571-020-00453-1. Nat Rev Clin Oncol. 2021. PMID: 33235325 No abstract available.
-
Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.Breast Cancer Res Treat. 2017 Nov;166(1):41-54. doi: 10.1007/s10549-017-4385-3. Epub 2017 Jul 24. Breast Cancer Res Treat. 2017. PMID: 28741274 Review.
-
Mechanisms of therapeutic CDK4/6 inhibition in breast cancer.Semin Oncol. 2017 Dec;44(6):385-394. doi: 10.1053/j.seminoncol.2018.01.006. Semin Oncol. 2017. PMID: 29935900 Review.
-
Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.Oncologist. 2017 Sep;22(9):1039-1048. doi: 10.1634/theoncologist.2017-0142. Epub 2017 Jul 13. Oncologist. 2017. PMID: 28706010 Free PMC article. Review.
-
CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib.Semin Oncol. 2017 Dec;44(6):395-403. doi: 10.1053/j.seminoncol.2018.03.006. Epub 2018 Mar 26. Semin Oncol. 2017. PMID: 29935901 Review.
Cited by
-
Feasibility of Adjuvant Treatment with Abemaciclib-Real-World Data from a Large German Breast Center.J Pers Med. 2022 Mar 2;12(3):382. doi: 10.3390/jpm12030382. J Pers Med. 2022. PMID: 35330381 Free PMC article.
-
Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER+/HER2- Breast Cancer.Clin Cancer Res. 2022 Jan 1;28(1):163-174. doi: 10.1158/1078-0432.CCR-21-1628. Epub 2021 Oct 13. Clin Cancer Res. 2022. PMID: 34645649 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
